With regards to possible anticancer therapy, we can mention senescence key signaling molecules such as p16, p21, and p53 that also operate as regulators of stemness, because a gain of stemness in cancer cells can influence tumor aggressiveness and clinical outcome. The gene discussed is CDKN2A; the disease is neoplasm.